NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ; Plos Medicine, 2007, vol. 4, issue 2, p e67, ISSN 15491676. ISBN 15491676.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef